Skip to main content
SpringerLink
Log in

The Remittive Effects of Alefacept

  • Published:
Journal of Cutaneous Medicine & Surgery

Abstract

The duration of response to treatment with alefacept has been assessed in patients with moderate to severe chronic plaque psoriasis who responded to alefacept therapy in phase 2 and phase 3 clinical studies. In a phase 2 trial, duration of response was based on time to retreatment with alefacept. In two phase 3 studies, the more objective measure of maintenance of a ≥50% reduction from baseline Psoriasis Area and Severity Index (PASI 50) was used. Two patient subsets were analyzed: (1) those who achieved a PASI 75 at any time during the trials and (2) those who achieved a Physician Global Assessment of “clear” or “almost clear” at any time during the trials. Regardless of the criterion used or the route of alefacept administration (intravenous or intramuscular), the median duration of response to alefacept therapy ranged from 7 to 10 months across the three studies. Alefacept is a remittive therapy for psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

FIGURE 1

Similar content being viewed by others

References

  1. J Koo M Lebwohl (1999) ArticleTitleDuration of remission of psoriasis therapies J Am Acad Dermatol 41 51–59 Occurrence Handle1:STN:280:DyaK1Mzjslaiug%3D%3D Occurrence Handle10411411

    CAS  PubMed  Google Scholar 

  2. SL McClure J Valentine KB Gordon (2002) ArticleTitleComparative tolerability of systemic treatments for plaque-type psoriasis Drug Saf 25 913–927 Occurrence Handle1:CAS:528:DC%2BD38XovVejurs%3D Occurrence Handle12381213

    CAS  PubMed  Google Scholar 

  3. M Lebwohl (2002) ArticleTitleNew developments in the treatment of psoriasis Arch Dermatol 138 686–688 Occurrence Handle12020234

    PubMed  Google Scholar 

  4. RP Kaplan DH Russell NJ Lowe (1983) ArticleTitleEtretinate therapy for psoriasis: clinical responses, remission times, epidermal DNA and polyamine responses J Am Acad Dermatol 8 95–102 Occurrence Handle1:STN:280:DyaL3s7js1Clug%3D%3D Occurrence Handle6826812 Occurrence Handle10.1016/S0190-9622(83)70012-5

    Article  CAS  PubMed  Google Scholar 

  5. VMR Heydendael PI Spuls BC Opmeer et al. (2003) ArticleTitleMethotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 658–665 Occurrence Handle10.1056/NEJMoa021359 Occurrence Handle1:CAS:528:DC%2BD3sXmtl2gs74%3D Occurrence Handle12917302

    Article  CAS  PubMed  Google Scholar 

  6. P Collins NJ Wainwright I Amorim et al. (1996) ArticleTitle8-MOP PUVA for psoriasis: a comparison of minimal phototoxic dose-based regimen with a skin-type approach Br J Dermatol 135 248–254 Occurrence Handle10.1046/j.1365-2133.1996.d01-983.x Occurrence Handle1:CAS:528:DyaK28XlsVajtLk%3D Occurrence Handle8881668

    Article  CAS  PubMed  Google Scholar 

  7. VP Vallat P Gilleaudeau L Battat et al. (1994) ArticleTitlePUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy J Exp Med 180 283–296 Occurrence Handle10.1084/jem.180.1.283 Occurrence Handle1:STN:280:DyaK2c3nsFersA%3D%3D Occurrence Handle7516410

    Article  CAS  PubMed  Google Scholar 

  8. JC Prinz (2003) ArticleTitleThe role of T cells in psoriasis J Eur Acad Dermatol Venereol 17 257–270 Occurrence Handle1:STN:280:DC%2BD3s3jslKqtA%3D%3D Occurrence Handle12702062

    CAS  PubMed  Google Scholar 

  9. P Singri DP West KB Gordon (2002) ArticleTitleBiologic therapy for psoriasis: the new therapeutic frontier Arch Dermatol 138 657–663 Occurrence Handle10.1001/archderm.138.5.657 Occurrence Handle1:CAS:528:DC%2BD38Xkt12rsrY%3D Occurrence Handle12020229

    Article  CAS  PubMed  Google Scholar 

  10. AB Gottlieb JD Bos (2002) ArticleTitleRecombinantly engineered human proteins: transforming the treatment of psoriasis Clin Immunol 105 105–116 Occurrence Handle10.1006/clim.2002.5289 Occurrence Handle1:CAS:528:DC%2BD38XpsF2ru7g%3D Occurrence Handle12482385

    Article  CAS  PubMed  Google Scholar 

  11. GT Miller PS Hochman W Meier et al. (1993) ArticleTitleSpecific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses J Exp Med 178 211–222 Occurrence Handle10.1084/jem.178.1.211 Occurrence Handle1:CAS:528:DyaK3sXksVOisr8%3D Occurrence Handle7686212

    Article  CAS  PubMed  Google Scholar 

  12. GR Majeau W Meier B Jimmo et al. (1994) ArticleTitleMechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice J Immunol 152 2753–2767 Occurrence Handle7511625 Occurrence Handle1:CAS:528:DyaK2cXisVajsLw%3D

    PubMed  CAS  Google Scholar 

  13. AJ da Silva M Brickelmaier GR Majeau et al. (2002) ArticleTitleAlefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells J Immunol 168 4462–4471 Occurrence Handle11970990 Occurrence Handle1:CAS:528:DC%2BD38Xjt12jtrY%3D

    PubMed  CAS  Google Scholar 

  14. JC Cooper G Morgan S Harding et al. (2003) ArticleTitleAlefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells Eur J Immunol 33 666–675 Occurrence Handle12616487 Occurrence Handle1:CAS:528:DC%2BD3sXisVChsrg%3D

    PubMed  CAS  Google Scholar 

  15. CN Ellis GG Krueger InstitutionalAuthorNamefor the Alefacept Clinical Study Group (2001) ArticleTitleTreatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 248–255 Occurrence Handle10.1056/NEJM200107263450403 Occurrence Handle1:CAS:528:DC%2BD3MXlvVKqs7Y%3D Occurrence Handle11474662

    Article  CAS  PubMed  Google Scholar 

  16. J-P Ortonne M Lebwohl CEM Griffiths InstitutionalAuthorNamefor the Alefacept Clinical Study Group (2003) ArticleTitleAlefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis Eur J Dermatol 13 117–123 Occurrence Handle1:CAS:528:DC%2BD3sXjsFyhsrY%3D Occurrence Handle12695125

    CAS  PubMed  Google Scholar 

  17. KB Gordon AK Vaishnaw J O’Gorman InstitutionalAuthorName for the Alefacept Clinical Study Group et al. (2003) ArticleTitleTreatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts Arch Dermatol 139 1563–1570 Occurrence Handle10.1001/archderm.139.12.1563 Occurrence Handle1:CAS:528:DC%2BD2cXivVamtw%3D%3D Occurrence Handle14676071

    Article  CAS  PubMed  Google Scholar 

  18. Chamian, F, Novitskaya, I, Khatcherian, A, et al. (2002) Therapeutic improvement induced by alefacept is linked to selective elimination of CD3+, CD8+, and CD103+ T cells from skin lesions of psoriasis vulgaris. Poster presented at the Psoriasis from Gene to Clinic 3rd International Symposium, 21-23 November 2002, London

  19. ME Sanders MW Makgoba SO Sharrow et al. (1988) ArticleTitleHuman memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production J Immunol 140 1401–1407 Occurrence Handle2894392 Occurrence Handle1:CAS:528:DyaL1cXhs1Gkuro%3D

    PubMed  CAS  Google Scholar 

  20. GR Majeau A Whitty K Yim et al. (1999) ArticleTitleLow affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation Cell Adhes Commun 7 267–279 Occurrence Handle1:CAS:528:DC%2BD3cXhtVOq Occurrence Handle10626910 Occurrence Handle10.3109/15419069909010808

    Article  CAS  PubMed  Google Scholar 

  21. GG Krueger KA Papp DB Stough InstitutionalAuthorName for the Alefacept Clinical Study Group et al. (2002) ArticleTitleA randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 821–833 Occurrence Handle12451365

    PubMed  Google Scholar 

  22. M Lebwohl E Christophers R Langley InstitutionalAuthorName for the Alefacept Clinical Study Group et al. (2003) ArticleTitleAn international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 719–727 Occurrence Handle12810502 Occurrence Handle1:CAS:528:DC%2BD3sXlsVamurw%3D

    PubMed  CAS  Google Scholar 

  23. GG Krueger CN Ellis (2003) ArticleTitleAlefacept therapy produces remission for patients with chronic plaque psoriasis Br J Dermatol 148 784–788 Occurrence Handle10.1046/j.1365-2133.2003.05239.x Occurrence Handle1:CAS:528:DC%2BD3sXkslemu7o%3D Occurrence Handle12752139

    Article  CAS  PubMed  Google Scholar 

  24. KB Gordon RG Langley (2003) ArticleTitleRemittive effects of intramuscular alefacept in psoriasis J Drugs Dermatol 2 624–628 Occurrence Handle14711140

    PubMed  Google Scholar 

  25. CS Carlin SR Feldman JG Krueger et al. (2004) ArticleTitleA 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis J Am Acad Dermatol 50 859–866 Occurrence Handle15153885

    PubMed  Google Scholar 

  26. AY Finlay MS Salek J Haney InstitutionalAuthorNamefor the Alefacept Clinical Study Group (2003) ArticleTitle. Dermatology 206 307–315 Occurrence Handle12771471 Occurrence Handle1:STN:280:DC%2BD3s3kslCmsg%3D%3D

    PubMed  CAS  Google Scholar 

  27. SR Feldman A Menter JY Koo InstitutionalAuthorNamefor the Alefacept Clinical Study Group (2004) ArticleTitleImproved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis Br J Dermatol 150 317–326 Occurrence Handle10.1111/j.1365-2133.2004.05697.x Occurrence Handle1:CAS:528:DC%2BD2cXivFGqur0%3D Occurrence Handle14996104

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA

    Gerald G. Krueger

  2. Department of Dermatology, 4B454 School of Medicine, University of Utah Health Sciences Center, 30 N 1900 E, Salt Lake City, UT, 84132-2409, USA

    Gerald G. Krueger

Authors
  1. Gerald G. Krueger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald G. Krueger.

About this article

Cite this article

Krueger, G.G. The Remittive Effects of Alefacept. J Cutan Med Surg 8 (Suppl 2), 10–14 (2004). https://doi.org/10.1007/s10227-004-9503-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10227-004-9503-2

Keywords

Search

Navigation